-
US futures point to a green open as virus concerns wane
-
Russell 2000 (US2000) eyes retest of key resistance
-
Market capitalization of Tesla (TSLA.US) set to exceed the one of Volkswagen
Equities around the world are recovering from yesterday’s sell-off coronavirus concerns waned for now. Situation during today’s session on Wall Street is likely to mimic this performance as US stock market futures point to a green opening. Meanwhile, Tesla is set to open with a market capitalization exceeding the one of Volkswagen, the world’s largest carmaker.
While three major US indices (S&P 500, Dow Jones and Nasdaq) are expected to return to ATHs today, Russell 2000 (US2000) continues to lag. The US small-cap index found strong resistance at the zone ranging around 1700 pts handle. The zone may be retested today thanks to upbeat moods on the global markets. A failure to break above could make the index look towards recent low at 1650 pts. Source: xStation5
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appJohnson & Johnson (JNJ.US) is a Dow Jones member that reported earnings ahead of the opening bell today. Results of the company came in line with estimates - Q4 EPS stood at $1.88 (expected $1.87) while revenue reached $20.74 billion (expected $20.8 billion). However, it should be noted that EPS was 5% lower than in the fourth quarter of 2018. However, the company issued an upbeat guidance for the current year - 2020 EPS is expected to fall in the $8.95-$9.10 range, marking a 23-25% YoY increase. Out of 7 Dow Jones members that reported earnings for Q4 2019, all showed revenue growth and 3 showed earnings growth. However, earnings are still 5.99% higher on the index level. Aggregate revenue growth for Dow Jones sits at 4.83% currently.
Johnson & Johnson (JNJ.US) made a break above the ATH earlier this week. However, the company is set to open 1.2% lower today following the release of Q4 earnings report. Stock should open within the zone marked by previous record peaks and it cannot be ruled out that recent break was a false signal. Should it be so, the first support to watch can be found at the zone ranging around $143.00 handle. Source: xStation5
Abbott Laboratories (ABT.US) also reported earnings ahead of the session open and also showed results more or less in line with estimates. Q4 EPS of $0.95 matched estimate while net sales of $8.31 billion marked a 0.6% beat. Earnings were 17.2% YoY higher while revenue jumped 7.1% YoY. Sales increased in all major segments with US Diabetes Care leading. US health care company highlighted over 60% YoY increase in organic sales of FreeStyle Libre - a glucose monitoring system approved by FDA in 2017.
Tesla (TSLA.US) continues to rally being fuelled by analysts’ upgrades. Analysts from Wedbush raised target for the stock from $370 to $550 today. Tesla is set to open higher today and exceed $100 billion market capitalization for the first time in history. This means that the US electric vehicle manufacturer will have a bigger capitalization than the world's largest carmaker - Volkswagen.
Abbott Laboratories (ABT.US) also broke to a fresh all-time high earlier this week. Company reported results that were in line with estimates therefore no major price reaction is expected at the open. Currently, stock is indicated to open 1.25% higher. The first near-term resistance to watch can be found at the 127.2% retracement of a downward move started in mid-2019 ($91.50). Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
